|
|
Post by standup on Aug 9, 2022 15:41:41 GMT -5
Deferred revenue means it has already been received from UTHR, but just not yet recognized due to some contingencies not yet satisfied. That is the accurate way for public companies. Does anyone know why a company might report different share count for Q2 results vs H1 results? Probably a weighted average. |
|
|
|
Post by peppy on Aug 9, 2022 15:52:20 GMT -5
Deferred revenue means it has already been received from UTHR, but just not yet recognized due to some contingencies not yet satisfied. That is the accurate way for public companies. Does anyone know why a company might report different share count for Q2 results vs H1 results? I believe that contingency is delivery, to UTHR. UTHR is in charge of Tyvasso DPI sales. |
|
|
|
Post by castlerockchris on Aug 9, 2022 15:56:01 GMT -5
Why not just tell the share holders what exactly is the royalty % of Tyvaso DPI? Because the last thing you want is every potential future partner basing the negotiations of their agreement with MNKD on the royalty payment MNKD gave to UT. At the time, the agreement with UT was made when MNKD's back was against the wall, with very little in the pipeline and even bleaker prospects as a going concern. I assume MNKD will be talking to bigger fish about even bigger opportunities than UT's DPI application once sales become more clear. Those big fish are going to squeeze margins aggressively on MNKD. Knowing what UT is paying only makes it easier for them. Shareholders have no right to confidential, non-public information like royalty percentages or what the plus is in the cost plus part of the agreement to manufacture Tyvaso DPI. At some point there may be the opportunity to interpolate the number based on public filings, but I doubt it. |
|
|
|
Post by brianrocco on Aug 9, 2022 16:50:12 GMT -5
Can't understand why MC not willing to disclose gross margin relationship on DPI manufacture that has been the focus of so much management effort and investment $. I do not like this lack of understanding and accountability. SG&A costs incredibly high (including admittedly failed promotion) and continue to exceed revenue (much less gross margins).
|
|
|
|
Post by mymann on Aug 9, 2022 16:51:15 GMT -5
Why not just tell the share holders what exactly is the royalty % of Tyvaso DPI? Because the last thing you want is every potential future partner basing the negotiations of their agreement with MNKD on the royalty payment MNKD gave to UT. At the time, the agreement with UT was made when MNKD's back was against the wall, with very little in the pipeline and even bleaker prospects as a going concern. I assume MNKD will be talking to bigger fish about even bigger opportunities than UT's DPI application once sales become more clear. Those big fish are going to squeeze margins aggressively on MNKD. Knowing what UT is paying only makes it easier for them. Shareholders have no right to confidential, non-public information like royalty percentages or what the plus is in the cost plus part of the agreement to manufacture Tyvaso DPI. At some point there may be the opportunity to interpolate the number based on public filings, but I doubt it. Mucho Gracias |
|
|
|
Post by letitride on Aug 9, 2022 16:51:30 GMT -5
I would believe the previously announced low double digit royalties should be able to be extrapolated from UTHR sales.
|
|
|
|
Post by mytakeonit on Aug 9, 2022 16:57:36 GMT -5
And it's all about guidance ... where we are headed. Hopefully you all know that what you heard was mostly covering the month of June. Everything is being set up to run smoothly. Hopefully.
Revenue seems to be growing. Next quarter should be a lot more exciting.
But, that's mytakeonit
|
|
|
|
Post by sla55 on Aug 9, 2022 17:00:23 GMT -5
|
|
|
|
Post by celo on Aug 9, 2022 17:17:57 GMT -5
Any discussion of what the more aggressive approach to doctors to sell more Afrezza entail? Cost a couple extra million
What about the couple more million on the Peds trial and pipeline? Be nice to get some details.
What about the cash going down so much. Did it go to Tyvaso development? At 35 million now...isnt that an ongoing concern? I've heard from Mannkind in the past, "we are good for the near future", only to have a share raise. Looks like the inventory went up with the V-go purchase. AR is up by 10 million from probably Tyvaso. Short term investments is up 30 million, that will be seen as revenue in the next qtr with Tyvaso, I guess.
Just seemed to be skimmed over real fast without much clarity. I don't want to be just told the future is fine, I want exactly how the balance sheet is going to get us there.
|
|
|
|
Post by Clement on Aug 9, 2022 17:39:30 GMT -5
Seeking Alpha misrepresented the cash situation. Surprise. $35M Cash plus $118M short term investments = $154.1M |
|
|
|
Post by sayhey24 on Aug 9, 2022 17:40:21 GMT -5
Any discussion of what the more aggressive approach to doctors to sell more Afrezza entail? Cost a couple extra million What about the couple more million on the Peds trial and pipeline? Be nice to get some details. What about the cash going down so much. Did it go to Tyvaso development? At 35 million now...isnt that an ongoing concern? I've heard from Mannkind in the past, "we are good for the near future", only to have a share raise. Looks like the inventory went up with the V-go purchase. AR is up by 10 million from probably Tyvaso. Short term investments is up 30 million, that will be seen as revenue in the next qtr with Tyvaso, I guess. Just seemed to be skimmed over real fast without much clarity. I don't want to be just told the future is fine, I want exactly how the balance sheet is going to get us there. Short term investments are 118,649 plus the 35,507 in cash and thats a nice chunk of change. I have no idea what the 32,596 is in long term investments is and how liquid that is. What do you mean "more aggressive approach to doctors to sell more Afrezza"? I might have missed that. What I heard is patients ask the doctors for afrezza and doctors don't prescribe. Thats should not be a surprise as afrezza is not really part of the standard of care. Mike said they had a promotional program which failed and they stopped it early after spending $6m but he gave no details. |
|
|
|
Post by cjm18 on Aug 9, 2022 17:44:44 GMT -5
Seeking Alpha misrepresented the cash situation. Surprise. $35M Cash plus $118M short term investments = $154.1M Just 154m? They had 233m last quarter. Net loss in q2 was 29M. There was no bragging about cash on hand at this call. There usually is. |
|
|
|
Post by sayhey24 on Aug 9, 2022 17:59:00 GMT -5
Seeking Alpha misrepresented the cash situation. Surprise. $35M Cash plus $118M short term investments = $154.1M Just 154m? They had 233m last quarter. Net loss in q2 was 29M. There was no bragging about cash on hand at this call. There usually is. 154 + 29 + 34 (long term investments) + 15 (V-Go) + 1(rounding) |
|
|
|
Post by agedhippie on Aug 9, 2022 18:01:20 GMT -5
What do you mean "more aggressive approach to doctors to sell more Afrezza"? I might have missed that. What I heard is patients ask the doctors for afrezza and doctors don't prescribe. Thats should not be a surprise as afrezza is not really part of the standard of care. Mike said they had a promotional program which failed and they stopped it early after spending $6m but he gave no details. Was that Seeing is Believing campaign? They were going to launch that in March I think after the earlier pilot in Q4 based on the Feb earnings call. |
|
|
|
Post by peppy on Aug 9, 2022 18:05:16 GMT -5
What do you mean "more aggressive approach to doctors to sell more Afrezza"? I might have missed that. What I heard is patients ask the doctors for afrezza and doctors don't prescribe. Thats should not be a surprise as afrezza is not really part of the standard of care. Mike said they had a promotional program which failed and they stopped it early after spending $6m but he gave no details. They were going to launch that in March I think after the earlier pilot in Q4 based on the Feb earnings call. I have been shocked, the physicians do not care that the CGM shows these people are more controlled. next. |
|
